MacroGenics Inc (MGNX)
Official siteHEALTHCARE • BIOTECHNOLOGY • NASDAQ
Market Cap: $140.60M
Last updated: Nov 17, 2026 at 11:06 AM ET
MacroGenics Inc (MGNX) Earnings: Report Dates and Results
MacroGenics (MGNX) is expected to report earnings on Mar 8, 2027. In the quarter ended Sep 30, 2026, MacroGenics reported EPS of -$0.34, below the -$0.10 estimate. It beat the EPS estimate in 4 of the last 8 quarters.
Earnings
Performance (10Y)
Upcoming Estimates
Next Report
MGNX has an expected report date of Mar 8, 2027.
MGNX Earnings Call
The latest MGNX earnings call transcript on file is labeled 2024Q2.
Read the 2024Q2 transcriptEarnings History
Of the 40 quarters below that had an estimate, MGNX beat 17 and missed 23. Revenue for the quarter ended Sep 30, 2026 was $18.67M, down 64.8% from $53.00M a year earlier.
| Quarter ended | EPS | Estimate | Range | Surprise | Result | YoY | Analysts | Revisions | Reported | Revenue |
|---|---|---|---|---|---|---|---|---|---|---|
| Sep 30, 2026 | -$0.34 | -$0.10 | -$0.17 - -$0.08 | -240.00% | Miss | -225.9% | 2 | 0 up, 1 down | Nov 11, 2026 | $18.67M |
| Jun 30, 2026 | -$0.27 | -$0.34 | -$0.70 - $1.71 | +20.59% | Beat | N/A | 4 | 0 up, 1 down | Aug 13, 2026 | $32.83M |
| Mar 31, 2026 | -$0.58 | -$0.55 | -$0.73 - -$0.23 | -5.45% | Miss | N/A | 4 | 0 up, 1 down | May 13, 2026 | $20.77M |
| Dec 31, 2025 | -$0.22 | -$0.27 | N/A | +18.40% | Beat | N/A | 2 | 0 up, 0 down | Mar 9, 2026 | $41.23M |
| Sep 30, 2025 | $0.27 | -$0.44 | N/A | +161.36% | Beat | -70.0% | 1 | 0 up, 1 down | Nov 12, 2025 | $53.00M |
| Jun 30, 2025 | -$0.57 | $0.38 | $0.38 - $0.38 | -250.00% | Miss | N/A | 1 | 0 up, 0 down | Aug 14, 2025 | $6.87M |
| Mar 31, 2025 | -$0.65 | -$0.69 | -$0.69 - -$0.69 | +5.80% | Beat | N/A | 1 | 1 up, 0 down | May 13, 2025 | $13.19M |
| Dec 31, 2024 | -$0.82 | -$0.59 | -$0.76 - -$0.42 | -38.64% | Miss | N/A | 2 | 4 up, 1 down | Mar 20, 2025 | $19.35M |
| Sep 30, 2024 | $0.90 | $0.60 | -$0.89 - $0.81 | +50.00% | Beat | N/A | 10 | 0 up, 0 down | Nov 5, 2024 | $110.71M |
| Jun 30, 2024 | -$0.89 | -$0.59 | -$0.85 - $0.13 | -50.85% | Miss | N/A | 11 | 1 up, 1 down | Aug 6, 2024 | $10.80M |
| Mar 31, 2024 | -$0.84 | -$0.64 | -$0.77 - -$0.55 | -31.25% | Miss | N/A | 11 | 1 up, 0 down | May 9, 2024 | $9.10M |
| Dec 31, 2023 | -$0.75 | -$0.15 | -$0.37 - $0.38 | -400.00% | Miss | -457.1% | 10 | 0 up, 1 down | Mar 7, 2024 | $10.72M |
| Sep 30, 2023 | -$0.52 | -$0.35 | -$0.80 - $0.29 | -48.57% | Miss | N/A | 10 | 0 up, 1 down | Nov 6, 2023 | $10.40M |
| Jun 30, 2023 | -$0.70 | -$0.50 | -$0.82 - -$0.18 | -40.00% | Miss | N/A | 9 | 0 up, 1 down | Aug 9, 2023 | $13.14M |
| Mar 31, 2023 | -$0.61 | $0.35 | -$0.82 - $1.44 | -274.29% | Miss | N/A | 10 | 0 up, 0 down | May 9, 2023 | $24.50M |
| Dec 31, 2022 | $0.21 | $0.10 | -$0.89 - $1.26 | +110.00% | Beat | N/A | 11 | 0 up, 2 down | Mar 15, 2023 | $73.10M |
| Sep 30, 2022 | -$0.40 | -$0.36 | -$0.91 - $0.17 | -11.11% | Miss | N/A | 11 | 0 up, 1 down | Nov 3, 2022 | $41.73M |
| Jun 30, 2022 | -$0.67 | -$0.97 | -$1.09 - -$0.61 | +30.93% | Beat | N/A | 11 | 1 up, 0 down | Aug 8, 2022 | $26.01M |
| Mar 31, 2022 | -$1.08 | -$0.85 | -$1.03 - -$0.68 | -27.06% | Miss | N/A | 10 | 1 up, 0 down | May 3, 2022 | $11.10M |
| Dec 31, 2021 | -$0.95 | -$0.81 | -$1.00 - -$0.71 | -17.28% | Miss | N/A | 11 | 0 up, 0 down | Feb 24, 2022 | $14.15M |
| Sep 30, 2021 | -$0.86 | -$0.71 | -$0.90 - -$0.14 | -21.13% | Miss | N/A | 9 | 0 up, 0 down | Nov 2, 2021 | $15.66M |
| Jun 30, 2021 | -$0.66 | -$0.41 | -$1.03 - $1.45 | -60.98% | Miss | N/A | 10 | N/A | Jul 29, 2021 | $30.76M |
| Mar 31, 2021 | -$0.90 | -$0.63 | -$0.88 - -$0.16 | -42.86% | Miss | N/A | 10 | N/A | Apr 29, 2021 | $16.88M |
| Dec 31, 2020 | -$0.04 | -$0.60 | -$1.05 - -$0.25 | +93.33% | Beat | N/A | 10 | N/A | Feb 25, 2021 | $52.69M |
| Sep 30, 2020 | -$0.66 | -$1.02 | -$1.10 - -$0.72 | +35.29% | Beat | N/A | 10 | N/A | Nov 4, 2020 | $18.25M |
| Jun 30, 2020 | -$0.94 | -$1.00 | -$1.12 - -$0.59 | +6.00% | Beat | N/A | 10 | N/A | Jul 30, 2020 | $20.26M |
| Mar 31, 2020 | -$0.91 | -$1.02 | -$1.17 - -$0.80 | +10.78% | Beat | N/A | 11 | N/A | May 5, 2020 | $13.68M |
| Dec 31, 2019 | -$0.62 | -$1.16 | -$1.42 - $0.22 | +46.55% | Beat | N/A | 12 | N/A | Feb 25, 2020 | $25.19M |
| Sep 30, 2019 | -$0.91 | -$1.11 | -$1.29 - -$0.30 | +18.02% | Beat | N/A | 11 | N/A | Nov 6, 2019 | $18.74M |
| Jun 30, 2019 | -$1.05 | -$1.07 | -$1.33 - -$0.38 | +1.87% | Beat | N/A | 12 | N/A | Jul 31, 2019 | $10.59M |
| Mar 31, 2019 | -$0.99 | -$0.87 | -$1.27 - -$0.37 | -13.79% | Miss | N/A | 13 | N/A | May 1, 2019 | $9.66M |
| Dec 31, 2018 | -$1.06 | -$1.02 | -$1.38 - -$0.60 | -3.92% | Miss | -135.8% | 11 | N/A | Feb 26, 2019 | $15.79M |
| Sep 30, 2018 | -$0.81 | -$1.30 | -$1.48 - -$1.05 | +37.69% | Beat | N/A | 11 | N/A | Nov 7, 2018 | $20.80M |
| Jun 30, 2018 | -$1.03 | -$1.21 | -$1.36 - -$0.94 | +14.88% | Beat | N/A | 10 | N/A | Aug 7, 2018 | $18.83M |
| Mar 31, 2018 | -$1.34 | -$1.10 | -$1.26 - -$0.86 | -21.82% | Miss | N/A | 11 | N/A | May 7, 2018 | $4.70M |
| Dec 31, 2017 | $2.96 | $2.21 | -$1.14 - $2.99 | +33.94% | Beat | N/A | 10 | N/A | Feb 27, 2018 | $152.36M |
| Sep 30, 2017 | -$1.28 | -$1.04 | -$1.21 - -$0.86 | -23.08% | Miss | N/A | 10 | N/A | Nov 8, 2017 | $1.66M |
| Jun 30, 2017 | -$1.14 | -$1.00 | -$1.17 - $1.01 | -14.00% | Miss | -201.8% | 11 | N/A | Aug 2, 2017 | $1.67M |
| Mar 31, 2017 | -$1.08 | -$0.91 | N/A | -18.68% | Miss | N/A | N/A | N/A | May 3, 2017 | $2.06M |
| Dec 31, 2016 | -$1.00 | -$0.89 | N/A | -12.36% | Miss | N/A | N/A | N/A | Feb 28, 2017 | $5.11M |
Annual EPS
EPS for the fiscal year ended Dec 31, 2025 was -$1.17, after -$1.65 the year before. It was -$1.73 for the year ended Dec 31, 2016, the oldest of the 10 fiscal years shown.
| Fiscal year ended | EPS | Change |
|---|---|---|
| Dec 31, 2025 | -$1.17 | N/A |
| Dec 31, 2024 | -$1.65 | N/A |
| Dec 31, 2023 | -$2.58 | N/A |
| Dec 31, 2022 | -$1.94 | N/A |
| Dec 31, 2021 | -$3.37 | N/A |
| Dec 31, 2020 | -$2.55 | N/A |
| Dec 31, 2019 | -$3.57 | N/A |
| Dec 31, 2018 | -$4.24 | N/A |
| Dec 31, 2017 | -$0.54 | N/A |
| Dec 31, 2016 | -$1.73 | N/A |
Earnings Calls
The only earnings call listed below, 2024Q2 for the period ended Jun 30, 2024, runs about 5,400 words across 13 speakers.
| Call | Period ending | Words | Speakers | Transcript |
|---|---|---|---|---|
| 2024Q2 | Jun 30, 2024 | 5,395 | 13 |
2024Q2 Earnings Call
Opening remarks
James Karrels CFO Thank you, operator. Good afternoon, and welcome to MacroGenics' conference call to discuss our third quarter 2024 financial and operational results. For anyone who has not had the chance to review these results, we issued a press release this afternoon outlining today's announcements. This release is available under the Investors tab on our website at macrogenics.com. You may also listen to this conference call via webcast on our website, where it will be archived for 30 days beginning approximately two hours after the call is completed. I would like to alert listeners that today's discussion will include statements about the company's future expectations, plans and prospects that constitute forward-looking statements for purposes of the Safe Harbor provision under the Private Securities Litigation Reform Act of 1995. Actual results may differ materially from those indicated by these forward-looking statements as a result of various important factors, including those discussed in the Risk Factors section of our annual, quarterly and current reports filed with the SEC. In addition, any forward-looking statements represent our views only as of today and should not be relied upon as representing our views as of any subsequent date. While we may elect to update these forward-looking statements at some point in the future, we specifically disclaim any obligation to do so even if our views change, except to the extent required by applicable law. And now, I'd like to turn the call over to Dr. Scott Koenig, President and Chief Executive Officer of MacroGenics.
Scott Koenig CEO Thank you, Jim. I'd like to welcome everyone participating via conference call and webcast today. I will provide key updates on our clinical programs this afternoon. But before I do so, let me first turn the call back to Jim, who will review our financial results.
James Karrels CFO Thank you, Scott. This afternoon, MacroGenics reported financial results for the quarter ended September 30, 2024, which highlight our financial position. As described in our release this afternoon, MacroGenics total revenue was $110.7 million for the quarter ended September 30, 2024, compared to total revenue of $10.4 million for the quarter ended September 30, 2023. The increase was primarily due to $100 million in milestones received from Incyte in August related to retifanlimab. Our research and development expenses were $40.5 million for the quarter ended September 30, 2024 compared to $30.1 million for the quarter ended September 30, 2023. The increase was primarily due to increased research and development costs related to the company's preclinical ADC pipeline, vobra duo and the TAMARACK clinical trial. Our selling, general and administrative expenses were $14.1 million for the quarter ended September 30, 2024 compared to $12.4 million for the quarter ended September 30, 2023.
Frequently Asked Questions About MGNX
When is MacroGenics's next earnings date?
MacroGenics's next earnings report is expected for Mar 8, 2027.
Did MGNX beat earnings estimates last quarter?
No. MacroGenics reported EPS of -$0.34 for the quarter ended Sep 30, 2026, below the -$0.10 estimate by 240.00%.
What EPS do analysts expect from MGNX next quarter?
The consensus EPS estimate for MacroGenics for the quarter ending Dec 31, 2026 is -$0.26 from 9 analysts, with estimates from -$0.48 to $0.33.
How often does MGNX beat earnings estimates?
MacroGenics beat the EPS estimate in 4 of the last 8 quarters, with an average surprise of -40.99%.
MGNX pages: Overview, Earnings, Forecast, Financials, Valuation, Competitors, Government Contracts